Red Light Holland highlights FDA-authorized study backing multi-session psilocybin therapy using PEX010

TripAdvisor, Inc.
FILAMENT HEALTH CORP

TripAdvisor, Inc.

TRIP

0.00

FILAMENT HEALTH CORP

FLHLF

0.00
  • Red Light Holland highlighted newly published Phase 1 clinical results in April 2026 from a U.S. FDA-authorized study using Filament Health’s PEX010 botanical psilocybin candidate.
  • Study evaluated a second guided psilocybin-assisted therapy session in metastatic cancer patients who only partially responded to an initial session.
  • Results showed meaningful improvements in anxiety, depression, and broader psychological well-being, with benefits lasting up to 24 weeks.
  • Safety profile remained favorable, with no serious adverse events reported despite higher dosing and optional booster use.
  • Update comes as Red Light Holland pursues proposed acquisition of Filament, positioning PEX010’s supply footprint across 70+ clinical sites as a strategic asset for multi-session treatment models.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Red Light Holland Corp. published the original content used to generate this news brief on April 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.